Novavax (NVAX) Operating Leases (2020 - 2024)
Historic Operating Leases for Novavax (NVAX) over the last 5 years, with Q4 2024 value amounting to $76.7 million.
- Novavax's Operating Leases fell 924.97% to $76.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76.7 million, marking a year-over-year decrease of 924.97%. This contributed to the annual value of $76.7 million for FY2024, which is 924.97% down from last year.
- Per Novavax's latest filing, its Operating Leases stood at $76.7 million for Q4 2024, which was down 924.97% from $84.5 million recorded in Q4 2023.
- Novavax's 5-year Operating Leases high stood at $84.5 million for Q4 2023, and its period low was $39.1 million during Q4 2021.
- Over the past 5 years, Novavax's median Operating Leases value was $76.7 million (recorded in 2024), while the average stood at $66.4 million.
- In the last 5 years, Novavax's Operating Leases crashed by 2208.74% in 2021 and then skyrocketed by 10790.21% in 2022.
- Novavax's Operating Leases (Quarter) stood at $50.2 million in 2020, then decreased by 22.09% to $39.1 million in 2021, then soared by 107.9% to $81.3 million in 2022, then rose by 3.91% to $84.5 million in 2023, then fell by 9.25% to $76.7 million in 2024.
- Its Operating Leases was $76.7 million in Q4 2024, compared to $84.5 million in Q4 2023 and $81.3 million in Q4 2022.